1101 GMT - AstraZeneca's China troubles seem manageable, Quilter Cheviot healthcare analyst Sheena Berry says in a note. The British pharma company facing potential charges from an import tax allegation against some of its employees in China creates a slight overhang but entails an amount that it can handle, the analyst says. "China has proven to be an overhang on the stock following the fraud investigations of several individuals, and questions remain on exactly what impact this might have on operations in China," she says. Shares are up 5.2% at 117.02 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 06, 2025 06:02 ET (11:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.